ClinicalTrials.gg
CompletedNCT02997501ADELOSUpdated Mar 4, 2024Results posted

T790M Plasma Testing Methodology Comparison and Clinical Validation

A Phase 3 interventional study of T790M+ Testing and Baseline Visit Blood & Urine Testing in Lung Cancer, sponsored by AstraZeneca. Completed at 7 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.

Enrollment
5th of 30
256 · median 52
Started
2016
with 4 others
Phase 3
4 of 30
1 open now
Registered
11th of 30
by date
Lead sponsor
10 of 30
AstraZeneca

Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 5th largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 3, and was the 11th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing osimertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS. And to assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy and are T790M mutation positive detected by any one of the four plasma testing platforms: Cobas/Super-ARMS/ digital PCR/NGS.

Read the detailed description

Objective: The primary objective of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS. And to assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy and are T790M mutation positive detected by any one of the four plasma testing platforms: Cobas/Super-ARMS/ digital PCR/NGS.

Study number of patients planned: Approximately 250 patients will be recruited in China.

Study Design: This is an open-label, multi-center testing and treatment study.

Target patient population: 250 locally advanced or metastatic EGFR mutation positive NSCLC patients with progression on a previous EGFR-TKI will be recruited.

Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitizing and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day. All AEs/SAEs would be reported in ASTRIS main study and would not be reported repeatedly in current study.

Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria. The study will be closed in a maximum period of 18 months after the last patient is enrolled. Contingencies will be made to ensure continued drug supply for patients who are still deriving benefit from AZD9291 at that time.

Study measures: Data collected will include patient demographics, smoking history, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutations status, T790M and sensitizing mutations status results and type of test performed), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS).

Statistical methods: The concordance of T790M resistance mutation testing between the Cobas test and each of other platforms will be calculated. The sensitivity, specificity, PPV and NPV of each testing platform (Super-ARMS, digital PCR, and NGS) will be calculated with the Cobas test as the reference. The Kappa coefficient will be calculated to measure the agreement of T790M mutation testing between the Cobas test and each of other platforms. Descriptive statistics will be provided for all variables, as appropriate. Continuous variables will be summarized by the number of observations, mean, standard deviation, median, interquartile range (Q1, Q3), minimum, and maximum. Categorical variables will be summarized by frequency counts and percentages for each category. The 95% confidence interval (CI) will be calculated as appropriate. PFS and OS, respectively, will be summarized using Kaplan-Meier estimates of the median time to event (progression and death) and quartiles together with their 95% confidence intervals.The chi-square test will be used to compare the sensitivity, specificity, and concordance between any of the two platforms using Cobas as reference testing in an exploratory manner.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Adults (according to China regulations for age of majority)
  3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or (stage IV) NSCLC, not amenable to curative surgery or radiotherapy.
  4. Patients who have progressed following prior therapy with an EGFR-TKI agent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who disagree to participate this study.
  2. Patients whose medical objection was recorded to use the existing data from medical practice for scientific research.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    AZD9291

    Single arm of AZD9291, starting dose of 80mg

    Procedure: T790M+ Testing · Procedure: Baseline Visit Blood & Urine Testing · Procedure: Baseline ECG · Procedure: Visual Slit-Lamp Testing · Drug: AZD9291 Dosing · Procedure: Plasma AZD9291 testing

Interventions

  • ProcedureT790M+ Testing

    The patient will need to have T790M+ testing

  • ProcedureBaseline Visit Blood & Urine Testing

    Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

  • ProcedureBaseline ECG

    ECG to ensure absence of any cardiac abnormality

  • ProcedureVisual Slit-Lamp Testing

    Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

  • Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)

  • ProcedurePlasma AZD9291 testing

    The patient will need to have plasma AZD9291 testing before treatment

06

What researchers measure

Primary outcomes

  1. Concordance

    To evaluate concordance of T790M plasma mutation testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.

    Time frame: Up to 6 months

  2. PFS Using Investigator Assessments According to RECIST v1.1

    To assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR- TKI therapy and are T790M mutation positive detected by any one of the four plasma testing platforms. PFS was defined using Response Evaluation Criteria In Solid Tumors version 1.1(RECIST v1.1).

    Time frame: The time from first dose of AZD9291 in this study until the date of disease progression as recorded in CRF or death (by any cause in the absence of progression), assessed up to 18 months

Secondary outcomes

  1. Testing Sensitivity, Specificity, PPV, NPV

    To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Super-ARMS/digital PCR/NGS by using Cobas as the reference.

    Time frame: Up to 6 months.

  2. Overall Response Rate (ORR)

    To assess the efficacy of AZD9291 monotherapy by assessment of ORR in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. ORR is defined as the percentage of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR.

    Time frame: From first patient first CT scan for RECIST assessment, till the last patient last CT scan, up to 22 months.

  3. 75% OS Duration

    To assess the efficacy of AZD9291 monotherapy by assessment of overall survival (OS) in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. 75% OS duration was calculated.

    Time frame: From first patient signed the consent to study completion, up to 22 months.

07

Results

Posted Mar 4, 2024

Participant flow

1. Provision of informed consent prior to any study specific procedures. 2. Adults (according to China regulations for age of majority). 3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy. 4. Patients who have progressed following prior therapy with an EGFR-TKI agent.

Participant flow — Overall Study
MilestoneExperimental
Started256
Completed256
Not completed0

Outcome measures

PrimaryConcordance

To evaluate concordance of T790M plasma mutation testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.

Time frame:
Up to 6 months
Reported as:
Number · percentage of aggrement
Concordance
percentage of aggrementExperimental
For T790M, referred to Cobas, the concordance for Super-ARMS91.3
For T790M, referred to Cobas, the concordance for 3D PCR66.8
For T790M, referred to Cobas, the concordance for NGS82.7
For T790M, referred to Cobas, the concordance for ddPCR86.1
For T790M, referred to Super-ARMS, the concordance for 3D PCR71.0
For T790M, referred to Super-ARMS, the concordance for NGS88.3
For T790M, referred to Super-ARMS, the concordance for ddPCR88.1
For T790M, referred to 3D PCR, the concordance for NGS76.5
For T790M, referred to 3D PCR, the concordance for ddPCR72.2
For T790M, referred to NGS, the concordance for ddPCR85.8
PrimaryPFS Using Investigator Assessments According to RECIST v1.1

To assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR- TKI therapy and are T790M mutation positive detected by any one of the four plasma testing platforms. PFS was defined using Response Evaluation Criteria In Solid Tumors version 1.1(RECIST v1.1).

Time frame:
The time from first dose of AZD9291 in this study until the date of disease progression as recorded in CRF or death (by any cause in the absence of progression), assessed up to 18 months
Reported as:
Median · months
PFS Using Investigator Assessments According to RECIST v1.1
monthsExperimental
As-treated Analysis Set (contained all patients who took at least one dose of AZD9291)9.7 (8.4 to 11.2)
T790M Positive in Plasma via Cobas at Baseline10.6 (8.5 to 13.8)
T790M Positive in Plasma via Super-ARMS at Baseline10.6 (8.7 to 12.5)
T790M Positive in Plasma via 3D PCR at Baseline9.7 (8.3 to 11.3)
T790M Positive in Plasma via NGS at Baseline11.0 (9.5 to 13.8)
T790M Positive in Plasma via ddPCR at Baseline10.5 (8.3 to 12.7)
SecondaryTesting Sensitivity, Specificity, PPV, NPV

To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Super-ARMS/digital PCR/NGS by using Cobas as the reference.

Time frame:
Up to 6 months.
Reported as:
Number · percentage
Testing Sensitivity, Specificity, PPV, NPV
percentageExperimental
sensitivity for Super-ARMS94.7
sensitivity for 3D PCR90.5
sensitivity for NGS98.9
sensitivity for ddPCR98.9
specificity for Super-ARMS89.3
specificity for 3D PCR52.5
specificity for NGS73.0
specificity for ddPCR78.5
PPV for Super-ARMS84.1
PPV for 3D PCR53.4
PPV for NGS68.6
PPV for ddPCR73.0
NPV for Super-ARMS96.6
NPV for 3D PCR90.2
NPV for NGS99.1
NPV for ddPCR99.2
SecondaryOverall Response Rate (ORR)

To assess the efficacy of AZD9291 monotherapy by assessment of ORR in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. ORR is defined as the percentage of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR.

Time frame:
From first patient first CT scan for RECIST assessment, till the last patient last CT scan, up to 22 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsExperimental
As-treated Analysis Set56.3 (48.4 to 63.9)
T790M Positive in Plasma via Cobas at Baseline60.7 (49.7 to 70.9)
T790M Positive in Plasma via Super-ARMS at Baseline62.4 (52.2 to 71.8)
T790M Positive in Plasma via 3D PCR at Baseline54.1 (45.7 to 62.3)
T790M Positive in Plasma via NGS at Baseline62.0 (53.1 to 70.4)
T790M Positive in Plasma via ddPCR at Baseline59.1 (49.3 to 68.4)
Secondary75% OS Duration

To assess the efficacy of AZD9291 monotherapy by assessment of overall survival (OS) in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. 75% OS duration was calculated.

Time frame:
From first patient signed the consent to study completion, up to 22 months.
Reported as:
Median · months
75% OS Duration
monthsExperimental
As-treated Analysis Set9.7 (7.5 to 12.7)
T790M Positive in Plasma via Cobas at Baseline10.5 (7.3 to 13.6)
T790M Positive in Plasma via Super-ARMS at Baseline10.7 (8.0 to 14.5)
T790M Positive in Plasma via 3D PCR at Baseline8.7 (7.3 to 12.1)
T790M Positive in Plasma via NGS at Baseline11.9 (8.7 to 15.3)
T790M Positive in Plasma via ddPCR at Baseline10.6 (8.0 to 14.3)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental
Mean58.54 ± 9.506
Sex: Female, Male
Sex: Female, Male(Participants)Experimental
Female160
Male96
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental
American Indian or Alaska Native0
Asian256
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
enrollment number
enrollment number(Participants)Experimental
Patients who have progressed following prior therapy with an EGFR-TKI agent.256
08

Study locations

7 sites
  • Research Site
    Changchun, 130012, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710038, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Oct 2018, 22 months.

Results were first posted in Mar 2024, 5 years 4 months after primary completion. A results delay was requested in Sep 2019.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 22 months is below that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2016
First posted
Dec 20, 2016
StartActual
Dec 23, 2016
Primary completionActual
Oct 24, 2018
CompletionActual
Oct 24, 2018
Results delay requested
Sep 18, 2019
Results first posted
Mar 4, 2024
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02997501
Lead sponsor
AstraZeneca
Collaborators
TigerMed
Responsible party
Sponsor
First posted
Dec 20, 2016
Start date
Dec 23, 2016
Primary completion
Oct 24, 2018
Completion
Oct 24, 2018
Results posted
Mar 4, 2024
Last update
Mar 4, 2024

Study contacts

Yilong WU
principal investigator · Guangdong General Hospita
Zhiyong LIANG
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion